Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0UZ1I
|
|||
| Former ID |
DIB009140
|
|||
| Drug Name |
S-33138
|
|||
| Synonyms |
N-[4-[2-[(3aS,9bR)-8-Cyano-1,2,3,3a,4,9b-hexahydro[1]benzopyrano[3,4-c]pyrrol-2-yl]ethyl]phenyl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 1 | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23N3O2
|
|||
| Canonical SMILES |
CC(=O)NC1=CC=C(C=C1)CCN2CC3COC4=C(C3C2)C=C(C=C4)C#N
|
|||
| InChI |
1S/C22H23N3O2/c1-15(26)24-19-5-2-16(3-6-19)8-9-25-12-18-14-27-22-7-4-17(11-23)10-20(22)21(18)13-25/h2-7,10,18,21H,8-9,12-14H2,1H3,(H,24,26)/t18-,21+/m0/s1
|
|||
| InChIKey |
ZDZWIQDJFWTDAM-GHTZIAJQSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Antagonist | [2], [3] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014544) | |||
| REF 2 | The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.